Friday 6 November 2026 Export CORT’s income statement to Excel — free account

Corcept Therapeutics Incorporated

Corcept Therapeutics Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $761.4 million, up 12.8% from fiscal 2024.

Revenue: +64.0%
EPS: +525.8%
Free cash flow: +161.0%

Quarter to September 2026, against a year earlier

72.99 1.36 +1.90%

Follow CORT

Alert me

Market cap: $7.8B
P/E: 47.5×
Fwd P/E: 39.8×
Dividend yield: —
F-score: 4/9
Altman Z: 14.11
Beneish M: −2.76
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Valuation Filings

Corcept Therapeutics Incorporated 10-Q filed Nov 3, 2026

Fiscal Q3 2026 · Period ended Sep 30, 2026 · Filed Nov 3, 2026 · accepted 4:11 PM ET · Document on sec.gov · Filing index

What changed

Part I, Item 2, Management’s Discussion and Analysis Part II, Item 1A, Risk Factors

Part II, Item 1A, Risk Factors, against the 10-Q filed Jul 29, 2026: 5 added · 7 removed · 76 modified; 2 with only figures updated; 8 moved without change

88 more changes in this Item, word by word, in Powerpack.

Corcept Therapeutics Incorporated 10-Q filed Nov 3, 2026

What changed

Stockrow Weekly